Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer : Detection in ascitic fluid and localization to primary sites and metastatic implants
The mechanisms by which metastatic ovarian cancer adheres to peritoneal surfaces are not well understood. A role for tumor-derived extracellular matrix adhesive molecules such as fibronectin (FN) has been proposed. Because oncofetal fibronectin (onfFN) isoforms function in the adhesion of trophoblas...
Gespeichert in:
| Veröffentlicht in: | Cancer 1998, Vol.82 (1), p.152-158 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 158 |
|---|---|
| container_issue | 1 |
| container_start_page | 152 |
| container_title | Cancer |
| container_volume | 82 |
| creator | MENZIN, A. W LORET DE MOLA, J. R BILKER, W. B WHEELER, J. E RUBIN, S. C FEINBERG, R. F |
| description | The mechanisms by which metastatic ovarian cancer adheres to peritoneal surfaces are not well understood. A role for tumor-derived extracellular matrix adhesive molecules such as fibronectin (FN) has been proposed. Because oncofetal fibronectin (onfFN) isoforms function in the adhesion of trophoblasts and have been identified in association with several malignancies, we sought to study onfFN in patients with advanced epithelial ovarian cancer.
Total FN was identified with the nonspecific anti-FN monoclonal antibody CAF. OnfFN was identified using the specific monoclonal antibodies FDC-6 and X18A4. These antibodies were applied to: 1) ascitic fluid from advanced epithelial ovarian cancer patients and peritoneal fluid from patients without pathologic conditions and 2) tissue sections of primary lesions and metastatic ovarian cancer implants. Comparative histologic specimens included normal ovarian tissue and small bowel implants of endometriosis.
When measured by sandwich enzyme-linked immunoadsorbent assay, all peritoneal fluids (32 malignant and 32 benign) contained marked quantities of total (CAF reactive) FN, although malignant ascites had higher concentrations than benign samples (173.2 +/- 36.8 microg/mL vs. 76.4 +/- 31.8 microg/mL; P = 0.001). Malignant ascites also had significantly higher levels of onfFN than benign peritoneal fluid (FDC-6: 3.4 +/- 0.6 vs. 0.9 +/- 0.2 microg/mL; and X18A4: 5.1 +/- 1.3 vs. 1.1 +/- 0.4 microg/mL; P = 0.0001). Immunohistochemical staining of malignant lesions revealed prominent localization of both CAF reactive FN and onfFN to the stroma surrounding epithelial tumor nests. More delicate fibrillar staining within tumor nests also was evident. In contrast, implants of endometriosis revealed strong stromal staining for CAF reactive FN but not for onfFN.
These results demonstrate the presence of onfFN in advanced ovarian malignancies. We speculate that onfFN may participate in tumor-associated peritoneal adhesive interactions. |
| doi_str_mv | 10.1002/(SICI)1097-0142(19980101)82:1<152::AID-CNCR19>3.0.CO;2-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79660913</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79660913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c316t-11de8ea42d4d64a8700bb48e236bc9d992dc041463259f9db2e132fc85c466aa3</originalsourceid><addsrcrecordid>eNo9kdtq3DAQhkVpSTdpH6Ggi1KSC2918kGbEhKcHgyhCz1A7oSsA1WxLdfSJrSPlSeMnHUXBNIw_z8zmg-AS4zWGCHy_vR7UzdnGPEyQ5iRU8x5hTDCZxXZ4A84J5vNVXOd1V_rb5hf0DVa19tzkuFnYHUwPQcrhFCV5YzevgTHIfxOYUlyegSOOCMV42QFHhpthuisUzI6P0BvoR-UtybKDlrXTn4wKroBpjMmSRIHeO_iLyj1nRyU0dCMKTSdSwZ_JycnB6jmzAQ38NrE2e6f_DIoF52Ctts5DeWgYeeV7Ny_fevo4Ti5Xk5_YXDRhCdFnwYJUc4214-dTO1fgRdWdsG8Xu4T8PPTxx_1l-xm-7mpr24yRXERM4y1qYxkRDNdMFmVCLUtqwyhRau45pxohRhmBSU5t1y3xGBKrKpyxYpCSnoC3u3rjpP_szMhit4FZbo0hPG7IEpeFIhjmoS3e6GafAiTsWL5h8BIzDiFmHGKmYyYyYj_OEWV3iLhFCLhFHucggok6q1IqVT6zTLDru2NPhRe-KX82yWflis7O6XFu3CQEYxKjhh9BGqiswE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79660913</pqid></control><display><type>article</type><title>Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer : Detection in ascitic fluid and localization to primary sites and metastatic implants</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Wiley Online Library</source><source>Wiley Free Content</source><source>Alma/SFX Local Collection</source><creator>MENZIN, A. W ; LORET DE MOLA, J. R ; BILKER, W. B ; WHEELER, J. E ; RUBIN, S. C ; FEINBERG, R. F</creator><creatorcontrib>MENZIN, A. W ; LORET DE MOLA, J. R ; BILKER, W. B ; WHEELER, J. E ; RUBIN, S. C ; FEINBERG, R. F</creatorcontrib><description>The mechanisms by which metastatic ovarian cancer adheres to peritoneal surfaces are not well understood. A role for tumor-derived extracellular matrix adhesive molecules such as fibronectin (FN) has been proposed. Because oncofetal fibronectin (onfFN) isoforms function in the adhesion of trophoblasts and have been identified in association with several malignancies, we sought to study onfFN in patients with advanced epithelial ovarian cancer.
Total FN was identified with the nonspecific anti-FN monoclonal antibody CAF. OnfFN was identified using the specific monoclonal antibodies FDC-6 and X18A4. These antibodies were applied to: 1) ascitic fluid from advanced epithelial ovarian cancer patients and peritoneal fluid from patients without pathologic conditions and 2) tissue sections of primary lesions and metastatic ovarian cancer implants. Comparative histologic specimens included normal ovarian tissue and small bowel implants of endometriosis.
When measured by sandwich enzyme-linked immunoadsorbent assay, all peritoneal fluids (32 malignant and 32 benign) contained marked quantities of total (CAF reactive) FN, although malignant ascites had higher concentrations than benign samples (173.2 +/- 36.8 microg/mL vs. 76.4 +/- 31.8 microg/mL; P = 0.001). Malignant ascites also had significantly higher levels of onfFN than benign peritoneal fluid (FDC-6: 3.4 +/- 0.6 vs. 0.9 +/- 0.2 microg/mL; and X18A4: 5.1 +/- 1.3 vs. 1.1 +/- 0.4 microg/mL; P = 0.0001). Immunohistochemical staining of malignant lesions revealed prominent localization of both CAF reactive FN and onfFN to the stroma surrounding epithelial tumor nests. More delicate fibrillar staining within tumor nests also was evident. In contrast, implants of endometriosis revealed strong stromal staining for CAF reactive FN but not for onfFN.
These results demonstrate the presence of onfFN in advanced ovarian malignancies. We speculate that onfFN may participate in tumor-associated peritoneal adhesive interactions.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/(SICI)1097-0142(19980101)82:1<152::AID-CNCR19>3.0.CO;2-1</identifier><identifier>PMID: 9428492</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York, NY: Wiley-Liss</publisher><subject>Adenocarcinoma, Clear Cell - chemistry ; Adenocarcinoma, Clear Cell - pathology ; Adenocarcinoma, Clear Cell - secondary ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal ; Ascitic Fluid - chemistry ; Ascitic Fluid - cytology ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Carcinoma - chemistry ; Carcinoma - pathology ; Carcinoma - secondary ; Carcinoma, Endometrioid - chemistry ; Carcinoma, Endometrioid - pathology ; Carcinoma, Endometrioid - secondary ; Cell Adhesion ; Coloring Agents ; Endometriosis - metabolism ; Endometriosis - pathology ; Enzyme-Linked Immunosorbent Assay ; Epithelium - metabolism ; Epithelium - pathology ; Female ; Female genital diseases ; Fibronectins - analysis ; Gynecology. Andrology. Obstetrics ; Humans ; Immunohistochemistry ; Intestinal Diseases - metabolism ; Intestinal Diseases - pathology ; Intestine, Small - metabolism ; Intestine, Small - pathology ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Ovarian Neoplasms - chemistry ; Ovarian Neoplasms - pathology ; Peritoneum - pathology ; Trophoblasts - pathology ; Tumors</subject><ispartof>Cancer, 1998, Vol.82 (1), p.152-158</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c316t-11de8ea42d4d64a8700bb48e236bc9d992dc041463259f9db2e132fc85c466aa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2107904$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9428492$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MENZIN, A. W</creatorcontrib><creatorcontrib>LORET DE MOLA, J. R</creatorcontrib><creatorcontrib>BILKER, W. B</creatorcontrib><creatorcontrib>WHEELER, J. E</creatorcontrib><creatorcontrib>RUBIN, S. C</creatorcontrib><creatorcontrib>FEINBERG, R. F</creatorcontrib><title>Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer : Detection in ascitic fluid and localization to primary sites and metastatic implants</title><title>Cancer</title><addtitle>Cancer</addtitle><description>The mechanisms by which metastatic ovarian cancer adheres to peritoneal surfaces are not well understood. A role for tumor-derived extracellular matrix adhesive molecules such as fibronectin (FN) has been proposed. Because oncofetal fibronectin (onfFN) isoforms function in the adhesion of trophoblasts and have been identified in association with several malignancies, we sought to study onfFN in patients with advanced epithelial ovarian cancer.
Total FN was identified with the nonspecific anti-FN monoclonal antibody CAF. OnfFN was identified using the specific monoclonal antibodies FDC-6 and X18A4. These antibodies were applied to: 1) ascitic fluid from advanced epithelial ovarian cancer patients and peritoneal fluid from patients without pathologic conditions and 2) tissue sections of primary lesions and metastatic ovarian cancer implants. Comparative histologic specimens included normal ovarian tissue and small bowel implants of endometriosis.
When measured by sandwich enzyme-linked immunoadsorbent assay, all peritoneal fluids (32 malignant and 32 benign) contained marked quantities of total (CAF reactive) FN, although malignant ascites had higher concentrations than benign samples (173.2 +/- 36.8 microg/mL vs. 76.4 +/- 31.8 microg/mL; P = 0.001). Malignant ascites also had significantly higher levels of onfFN than benign peritoneal fluid (FDC-6: 3.4 +/- 0.6 vs. 0.9 +/- 0.2 microg/mL; and X18A4: 5.1 +/- 1.3 vs. 1.1 +/- 0.4 microg/mL; P = 0.0001). Immunohistochemical staining of malignant lesions revealed prominent localization of both CAF reactive FN and onfFN to the stroma surrounding epithelial tumor nests. More delicate fibrillar staining within tumor nests also was evident. In contrast, implants of endometriosis revealed strong stromal staining for CAF reactive FN but not for onfFN.
These results demonstrate the presence of onfFN in advanced ovarian malignancies. We speculate that onfFN may participate in tumor-associated peritoneal adhesive interactions.</description><subject>Adenocarcinoma, Clear Cell - chemistry</subject><subject>Adenocarcinoma, Clear Cell - pathology</subject><subject>Adenocarcinoma, Clear Cell - secondary</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal</subject><subject>Ascitic Fluid - chemistry</subject><subject>Ascitic Fluid - cytology</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Carcinoma - chemistry</subject><subject>Carcinoma - pathology</subject><subject>Carcinoma - secondary</subject><subject>Carcinoma, Endometrioid - chemistry</subject><subject>Carcinoma, Endometrioid - pathology</subject><subject>Carcinoma, Endometrioid - secondary</subject><subject>Cell Adhesion</subject><subject>Coloring Agents</subject><subject>Endometriosis - metabolism</subject><subject>Endometriosis - pathology</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Epithelium - metabolism</subject><subject>Epithelium - pathology</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Fibronectins - analysis</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Intestinal Diseases - metabolism</subject><subject>Intestinal Diseases - pathology</subject><subject>Intestine, Small - metabolism</subject><subject>Intestine, Small - pathology</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Ovarian Neoplasms - chemistry</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Peritoneum - pathology</subject><subject>Trophoblasts - pathology</subject><subject>Tumors</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kdtq3DAQhkVpSTdpH6Ggi1KSC2918kGbEhKcHgyhCz1A7oSsA1WxLdfSJrSPlSeMnHUXBNIw_z8zmg-AS4zWGCHy_vR7UzdnGPEyQ5iRU8x5hTDCZxXZ4A84J5vNVXOd1V_rb5hf0DVa19tzkuFnYHUwPQcrhFCV5YzevgTHIfxOYUlyegSOOCMV42QFHhpthuisUzI6P0BvoR-UtybKDlrXTn4wKroBpjMmSRIHeO_iLyj1nRyU0dCMKTSdSwZ_JycnB6jmzAQ38NrE2e6f_DIoF52Ctts5DeWgYeeV7Ny_fevo4Ti5Xk5_YXDRhCdFnwYJUc4214-dTO1fgRdWdsG8Xu4T8PPTxx_1l-xm-7mpr24yRXERM4y1qYxkRDNdMFmVCLUtqwyhRau45pxohRhmBSU5t1y3xGBKrKpyxYpCSnoC3u3rjpP_szMhit4FZbo0hPG7IEpeFIhjmoS3e6GafAiTsWL5h8BIzDiFmHGKmYyYyYj_OEWV3iLhFCLhFHucggok6q1IqVT6zTLDru2NPhRe-KX82yWflis7O6XFu3CQEYxKjhh9BGqiswE</recordid><startdate>1998</startdate><enddate>1998</enddate><creator>MENZIN, A. W</creator><creator>LORET DE MOLA, J. R</creator><creator>BILKER, W. B</creator><creator>WHEELER, J. E</creator><creator>RUBIN, S. C</creator><creator>FEINBERG, R. F</creator><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1998</creationdate><title>Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer : Detection in ascitic fluid and localization to primary sites and metastatic implants</title><author>MENZIN, A. W ; LORET DE MOLA, J. R ; BILKER, W. B ; WHEELER, J. E ; RUBIN, S. C ; FEINBERG, R. F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c316t-11de8ea42d4d64a8700bb48e236bc9d992dc041463259f9db2e132fc85c466aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adenocarcinoma, Clear Cell - chemistry</topic><topic>Adenocarcinoma, Clear Cell - pathology</topic><topic>Adenocarcinoma, Clear Cell - secondary</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal</topic><topic>Ascitic Fluid - chemistry</topic><topic>Ascitic Fluid - cytology</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Carcinoma - chemistry</topic><topic>Carcinoma - pathology</topic><topic>Carcinoma - secondary</topic><topic>Carcinoma, Endometrioid - chemistry</topic><topic>Carcinoma, Endometrioid - pathology</topic><topic>Carcinoma, Endometrioid - secondary</topic><topic>Cell Adhesion</topic><topic>Coloring Agents</topic><topic>Endometriosis - metabolism</topic><topic>Endometriosis - pathology</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Epithelium - metabolism</topic><topic>Epithelium - pathology</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Fibronectins - analysis</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Intestinal Diseases - metabolism</topic><topic>Intestinal Diseases - pathology</topic><topic>Intestine, Small - metabolism</topic><topic>Intestine, Small - pathology</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Ovarian Neoplasms - chemistry</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Peritoneum - pathology</topic><topic>Trophoblasts - pathology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MENZIN, A. W</creatorcontrib><creatorcontrib>LORET DE MOLA, J. R</creatorcontrib><creatorcontrib>BILKER, W. B</creatorcontrib><creatorcontrib>WHEELER, J. E</creatorcontrib><creatorcontrib>RUBIN, S. C</creatorcontrib><creatorcontrib>FEINBERG, R. F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MENZIN, A. W</au><au>LORET DE MOLA, J. R</au><au>BILKER, W. B</au><au>WHEELER, J. E</au><au>RUBIN, S. C</au><au>FEINBERG, R. F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer : Detection in ascitic fluid and localization to primary sites and metastatic implants</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1998</date><risdate>1998</risdate><volume>82</volume><issue>1</issue><spage>152</spage><epage>158</epage><pages>152-158</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>The mechanisms by which metastatic ovarian cancer adheres to peritoneal surfaces are not well understood. A role for tumor-derived extracellular matrix adhesive molecules such as fibronectin (FN) has been proposed. Because oncofetal fibronectin (onfFN) isoforms function in the adhesion of trophoblasts and have been identified in association with several malignancies, we sought to study onfFN in patients with advanced epithelial ovarian cancer.
Total FN was identified with the nonspecific anti-FN monoclonal antibody CAF. OnfFN was identified using the specific monoclonal antibodies FDC-6 and X18A4. These antibodies were applied to: 1) ascitic fluid from advanced epithelial ovarian cancer patients and peritoneal fluid from patients without pathologic conditions and 2) tissue sections of primary lesions and metastatic ovarian cancer implants. Comparative histologic specimens included normal ovarian tissue and small bowel implants of endometriosis.
When measured by sandwich enzyme-linked immunoadsorbent assay, all peritoneal fluids (32 malignant and 32 benign) contained marked quantities of total (CAF reactive) FN, although malignant ascites had higher concentrations than benign samples (173.2 +/- 36.8 microg/mL vs. 76.4 +/- 31.8 microg/mL; P = 0.001). Malignant ascites also had significantly higher levels of onfFN than benign peritoneal fluid (FDC-6: 3.4 +/- 0.6 vs. 0.9 +/- 0.2 microg/mL; and X18A4: 5.1 +/- 1.3 vs. 1.1 +/- 0.4 microg/mL; P = 0.0001). Immunohistochemical staining of malignant lesions revealed prominent localization of both CAF reactive FN and onfFN to the stroma surrounding epithelial tumor nests. More delicate fibrillar staining within tumor nests also was evident. In contrast, implants of endometriosis revealed strong stromal staining for CAF reactive FN but not for onfFN.
These results demonstrate the presence of onfFN in advanced ovarian malignancies. We speculate that onfFN may participate in tumor-associated peritoneal adhesive interactions.</abstract><cop>New York, NY</cop><pub>Wiley-Liss</pub><pmid>9428492</pmid><doi>10.1002/(SICI)1097-0142(19980101)82:1<152::AID-CNCR19>3.0.CO;2-1</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 1998, Vol.82 (1), p.152-158 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79660913 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Wiley Online Library; Wiley Free Content; Alma/SFX Local Collection |
| subjects | Adenocarcinoma, Clear Cell - chemistry Adenocarcinoma, Clear Cell - pathology Adenocarcinoma, Clear Cell - secondary Adult Aged Aged, 80 and over Antibodies, Monoclonal Ascitic Fluid - chemistry Ascitic Fluid - cytology Biological and medical sciences Biomarkers, Tumor - analysis Carcinoma - chemistry Carcinoma - pathology Carcinoma - secondary Carcinoma, Endometrioid - chemistry Carcinoma, Endometrioid - pathology Carcinoma, Endometrioid - secondary Cell Adhesion Coloring Agents Endometriosis - metabolism Endometriosis - pathology Enzyme-Linked Immunosorbent Assay Epithelium - metabolism Epithelium - pathology Female Female genital diseases Fibronectins - analysis Gynecology. Andrology. Obstetrics Humans Immunohistochemistry Intestinal Diseases - metabolism Intestinal Diseases - pathology Intestine, Small - metabolism Intestine, Small - pathology Medical sciences Middle Aged Neoplasm Staging Ovarian Neoplasms - chemistry Ovarian Neoplasms - pathology Peritoneum - pathology Trophoblasts - pathology Tumors |
| title | Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer : Detection in ascitic fluid and localization to primary sites and metastatic implants |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T06%3A46%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20oncofetal%20fibronectin%20in%20patients%20with%20advanced%20epithelial%20ovarian%20cancer%20:%20Detection%20in%20ascitic%20fluid%20and%20localization%20to%20primary%20sites%20and%20metastatic%20implants&rft.jtitle=Cancer&rft.au=MENZIN,%20A.%20W&rft.date=1998&rft.volume=82&rft.issue=1&rft.spage=152&rft.epage=158&rft.pages=152-158&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/(SICI)1097-0142(19980101)82:1%3C152::AID-CNCR19%3E3.0.CO;2-1&rft_dat=%3Cproquest_cross%3E79660913%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79660913&rft_id=info:pmid/9428492&rfr_iscdi=true |